Physician profile
Hulbert DO
NPI 1679733760
$6,713.59
in general payments reported to CMS, 2019-2025
40 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $192 · 2021: $475 · 2022: $1,874 · 2023: $1,805 · 2024: $947 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,172.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,030.91 | 2020-2025 | Aveir, Assurity, Cardiomems |
| Heartflow, INC. | $708.68 | 2024-2025 | |
| Aop Health US, LLC | $497.47 | 2025 | Rapiblyk |
| Boston Scientific Corporation | $450.64 | 2022-2024 | Watchman, Watchman Access System, Versacross Access Solution |
| Edwards Lifesciences Corporation | $443.40 | 2021-2023 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $353.27 | 2022-2023 | Xarelto |
| Shockwave Medical, INC | $307.35 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $287.49 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $272.51 | 2022-2025 | Camzyos, Eliquis |
| Impulse Dynamics (USA) INC. | $251.28 | 2022 | |
| Amgen INC. | $247.37 | 2020-2025 | Repatha, Repatha |
| Astellas Pharma US INC | $199.94 | 2022 | |
| Biotronik INC. | $147.75 | 2022-2023 | Biomonitor |
| Lexicon Pharmaceuticals, INC. | $136.46 | 2023-2024 | Inpefa |
| Novartis Pharmaceuticals Corporation | $133.86 | 2022-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $119.83 | 2022-2025 | |
| Kestra Medical Technology Services, INC. | $113.28 | 2022-2025 | Assure Wcd |
| Biosense Webster, INC. | $100.00 | 2021 | |
| Cvrx, INC. | $90.43 | 2023-2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $83.83 | 2022-2024 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.95 | 2022-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $65.15 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $64.60 | 2022-2023 | Farxiga, Brilinta |
| Kiniksa Pharmaceuticals, Ltd. | $59.31 | 2021-2023 | Arcalyst |
| Medtronic, INC. | $50.00 | 2023 | Onyx Frontier |
| Merck Sharp & Dohme LLC | $49.42 | 2022-2025 | Verquvo |
| Tactile Systems Technology INC | $43.18 | 2024 | Flexitouch Plus, Entre Plus |
| Ucb, INC. | $39.09 | 2025 | Bimzelx |
| Kiniksa Pharmaceuticals International, Plc | $37.17 | 2024 | Arcalyst |
| Angiodynamics, INC. | $32.84 | 2024 | Angiovac |
| Atricure, INC. | $32.03 | 2023 | |
| Koya Medical, INC. | $31.70 | 2025 | Koya Medical, Dayspring |
| Esperion Therapeutics, INC. | $29.73 | 2023-2024 | Nexletol |
| Daiichi Sankyo INC. | $27.38 | 2025 | Injectafer |
| Organogenesis INC. | $27.18 | 2024 | |
| Inspire Medical Systems, INC. | $18.24 | 2024 | Inspire |
| Novo Nordisk INC | $17.80 | 2024 | Ozempic, Rybelsus |
| Philips North America LLC | $17.53 | 2021 | |
| Nevro Corp. | $15.55 | 2023 | Senza |
| Baxter Healthcare | $13.99 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hulbert DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.